Despite a murky economic forecast, 60 percent of healthcare and life science investors are looking to increase their merger and acquisition activity in 2023, according to a new report from KPMG.
In biopharma, the report found that 64 percent of investors said that they were more likely to acquire early-stage, innovative companies in 2023, according to a Jan. 9 KPMG news release.
"2022 is a story of both tailwinds and headwinds," Ash Shehata, KPMG national sector leader healthcare and life sciences, said. "Hospital systems are dealing with rising labor and supply costs while biopharma and medical device companies have been exposed to supply chain, logistics, and labor issues that slow down production. Now is the time for [healthcare and life sciences] leaders to adjust their strategies to build durability and resilience within their companies."